Sponsor:
BriaCell Therapeutics Corporation
Code:
NCT06072612
Conditions
Breast Cancer
Metastatic Breast Cancer
Breast Neoplasm
Breast Cancer Metastatic
End Stage Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
SV-BR-1-GM
Cyclophosphamide
Interferon infiltration of the inoculation site
Retifanlimab
Treatment of Physician's Choice
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by BriaCell Therapeutics Corporation on 2025-07-31.